Drug Trial Radar · NCT03051009
Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Last checked: Nov 19, 2026Latest source record: Sep 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
503
Actual
Start
Jan 11, 2017
Primary completion
Sep 11, 2018
Study completion Sep 11, 2018
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Demonstrate the safety and tolerability of desmopressin ODT during long-term treatment of subjects with nocturia due to nocturnal polyuria, for up to 1 year
Conditions
- Nocturia
Interventions
Desmopressin ODT 25 μgDrug
Desmopressin ODT 50 μgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The frequency and severity of adverse eventsTime frame: Up to 1 year
- Clinically significant changes in laboratory values and vital signsTime frame: Up to 1 year
- The incidence and severity of hyponatraemiaTime frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational site (there may be other sites in this country)
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.